Literature DB >> 24014140

Treatment strategies for the prevention of heart failure.

Justin L Grodin1, W H Wilson Tang.   

Abstract

With the astounding morbidity and mortality associated with heart failure (HF), preventive approaches have been explored. Controlling hypertension to prevent HF is well-established, especially with sodium restriction and thiazide-based antihypertensive therapies showing potential advantages. Control of dyslipidemia with aggressive statin therapy is particularly beneficial in preventing HF in the setting of acute coronary syndrome. The HOPE study also established the benefit of ACE inhibitors in the prevention of HF in high-risk subjects. Meanwhile old data supporting tight glycemic control in preventing HF have not been confirmed, suggesting the complexity of diabetic cardiomyopathy. Avoiding tobacco use and other known cardiotoxins are likely helpful. While there has been substantial development in identifying biomarkers predicting future development of HF, therapeutic interdiction guided by biomarker levels have yet to be established, even though it offers hope in modulating the natural history of the development of HF in at-risk individuals.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24014140      PMCID: PMC3823759          DOI: 10.1007/s11897-013-0154-8

Source DB:  PubMed          Journal:  Curr Heart Fail Rep        ISSN: 1546-9530


  108 in total

1.  Natural history of isolated bundle branch block.

Authors:  G J Fahy; S L Pinski; D P Miller; N McCabe; C Pye; M J Walsh; K Robinson
Journal:  Am J Cardiol       Date:  1996-06-01       Impact factor: 2.778

2.  Cardiovascular features of heart failure with preserved ejection fraction versus nonfailing hypertensive left ventricular hypertrophy in the urban Baltimore community: the role of atrial remodeling/dysfunction.

Authors:  Vojtech Melenovsky; Barry A Borlaug; Boaz Rosen; Ilan Hay; Luigi Ferruci; Christopher H Morell; Edward G Lakatta; Samer S Najjar; David A Kass
Journal:  J Am Coll Cardiol       Date:  2006-12-29       Impact factor: 24.094

3.  Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction.

Authors:  A M Richards; M G Nicholls; T G Yandle; C Frampton; E A Espiner; J G Turner; R C Buttimore; J G Lainchbury; J M Elliott; H Ikram; I G Crozier; D W Smyth
Journal:  Circulation       Date:  1998-05-19       Impact factor: 29.690

4.  Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study.

Authors:  L Hansson; L H Lindholm; T Ekbom; B Dahlöf; J Lanke; B Scherstén; P O Wester; T Hedner; U de Faire
Journal:  Lancet       Date:  1999-11-20       Impact factor: 79.321

5.  Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension)

Authors:  B Dahlöf; L H Lindholm; L Hansson; B Scherstén; T Ekbom; P O Wester
Journal:  Lancet       Date:  1991-11-23       Impact factor: 79.321

6.  The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease.

Authors:  J Kjekshus; T R Pedersen; A G Olsson; O Faergeman; K Pyörälä
Journal:  J Card Fail       Date:  1997-12       Impact factor: 5.712

7.  Plasma brain natriuretic peptide is a biochemical marker for the prediction of progressive ventricular remodeling after acute myocardial infarction.

Authors:  N Nagaya; T Nishikimi; Y Goto; Y Miyao; Y Kobayashi; I Morii; S Daikoku; T Matsumoto; S Miyazaki; H Matsuoka; S Takishita; K Kangawa; H Matsuo; H Nonogi
Journal:  Am Heart J       Date:  1998-01       Impact factor: 4.749

8.  Prognostic significance of exercise-induced left bundle-branch block.

Authors:  T A Grady; A C Chiu; C E Snader; T H Marwick; J D Thomas; F J Pashkow; M S Lauer
Journal:  JAMA       Date:  1998-01-14       Impact factor: 56.272

9.  Structural and functional alterations of the intramyocardial coronary arterioles in patients with arterial hypertension.

Authors:  B Schwartzkopff; W Motz; H Frenzel; M Vogt; S Knauer; B E Strauer
Journal:  Circulation       Date:  1993-09       Impact factor: 29.690

10.  The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.

Authors:  M Packer; M R Bristow; J N Cohn; W S Colucci; M B Fowler; E M Gilbert; N H Shusterman
Journal:  N Engl J Med       Date:  1996-05-23       Impact factor: 91.245

View more
  2 in total

1.  Race and Sex Differences in Modifiable Risk Factors and Incident Heart Failure.

Authors:  Danielle M Kubicki; Meng Xu; Elvis A Akwo; Debra Dixon; Daniel Muñoz; William J Blot; Thomas J Wang; Loren Lipworth; Deepak K Gupta
Journal:  JACC Heart Fail       Date:  2019-11-11       Impact factor: 12.035

2.  Incidence of Hospitalization for Heart Failure and Case-Fatality Among 3.25 Million People With and Without Diabetes Mellitus.

Authors:  David A McAllister; Stephanie H Read; Jan Kerssens; Shona Livingstone; Stuart McGurnaghan; Pardeep Jhund; John Petrie; Naveed Sattar; Colin Fischbacher; Soren Lund Kristensen; John McMurray; Helen M Colhoun; Sarah H Wild
Journal:  Circulation       Date:  2018-12-11       Impact factor: 29.690

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.